Keloid Scarring: Treatment and Pathophysiology
This trial is active, not recruiting.
|Treatments||5- fluorouracil, radiotherapy, triamcinolone|
|Sponsor||Queen Mary University of London|
|Start date||February 2011|
|End date||January 2012|
|Trial size||100 participants|
|Trial identifier||NCT01295099, KS001|
To clarify the mechanisms of Keloid scar formation.
Elucidate the action and therapeutic value of 5-FU in Keloid scar treatment
Identify the genetic link with Keloid scar formation.
Quantify the psychological/social impact in keloid scarring patients
|Intervention model||single group assignment|
Keloid Scar Reduction
time frame: 18 months
Male or female participants from 18 years up to 85 years old.
Inclusion Criteria: - Adult ( > 18 years old). - Keloid scarring present. - Able to understand and give informed consent. - Patients giving informed consent to donate keloidal or non-affected skin when that is redundant after a procedure (i.e. BBR, Abdominoplasty). - Patients with a strong familial pedigree of keloid scar formation. Exclusion Criteria: - Open wound at or proximity of the lesion - Infected lesion - Pregnant or planning pregnancy in the near future - Lactating (Breast Feeding) - Abnormal renal or liver function tests - Atrophic scars - Patient under 18 years of age - Immunocompromised - OR immunosuppressed
|Official title||Keloid Scarring:A Randomized Clinical and Laboratory Based Study on the Treatment and Differentiation Factors of the Local Disease|
Call for more information